Royce & Associates LP Has $3.39 Million Stake in Accuray Incorporated (NASDAQ:ARAY)

Royce & Associates LP lowered its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 34.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,882,369 shares of the medical equipment provider’s stock after selling 1,000,167 shares during the period. Royce & Associates LP owned about 1.88% of Accuray worth $3,388,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Renaissance Technologies LLC boosted its position in shares of Accuray by 0.3% during the 2nd quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock valued at $5,118,000 after acquiring an additional 7,500 shares in the last quarter. Armistice Capital LLC bought a new position in Accuray during the second quarter worth about $910,000. Bank of New York Mellon Corp grew its stake in shares of Accuray by 3.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 279,426 shares of the medical equipment provider’s stock valued at $509,000 after purchasing an additional 8,864 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Accuray in the 3rd quarter valued at approximately $418,000. Finally, Assenagon Asset Management S.A. lifted its position in shares of Accuray by 127.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 164,999 shares of the medical equipment provider’s stock worth $297,000 after buying an additional 92,357 shares during the period. Institutional investors own 64.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com cut Accuray from a “buy” rating to a “hold” rating in a research report on Friday.

Accuray Price Performance

Shares of Accuray stock opened at $1.70 on Tuesday. The stock has a market capitalization of $170.97 million, a price-to-earnings ratio of -10.00 and a beta of 1.40. The firm’s 50-day moving average price is $1.86 and its two-hundred day moving average price is $1.83. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. Accuray Incorporated has a 1-year low of $1.40 and a 1-year high of $3.05.

Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm had revenue of $101.55 million during the quarter, compared to analysts’ expectations of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same period last year, the firm posted ($0.03) EPS. On average, equities analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.